VivoSim Labs, Inc. Total Assets
VivoSim Labs, Inc. total assets. Based on the latest financial reports, VivoSim Labs, Inc. (VIVS) holds total assets worth $3.85 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see VivoSim Labs, Inc. (VIVS) total market value for the company's overall valuation and market capitalisation.
Total Assets of VivoSim Labs, Inc. (2011–2026)
Total assets of VivoSim Labs, Inc. from 2011 to 2026. This chart illustrates how VivoSim Labs, Inc.'s total assets have evolved over time, based on quarterly financial data. See VivoSim Labs, Inc. stock quote for real-time trading data and today's change.
VivoSim Labs, Inc. - Asset Composition Analysis
VivoSim Labs, Inc. Total Assets Breakdown (March 2026)
VivoSim Labs, Inc. total assets breakdown as of March 2026. VivoSim Labs, Inc.'s total assets of $3.85 Million consist of 89.7% current assets and 10.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.0% |
| Accounts Receivable | $1.05 Million | 14.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2026)
This chart illustrates how VivoSim Labs, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is VivoSim Labs, Inc.'s working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: VivoSim Labs, Inc.'s current assets represent 89.7% of total assets in 2026, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 68.0% of total assets in 2026, up from 41.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 14.2% of total assets.
VivoSim Labs, Inc. Competitors by Total Assets
Key competitors of VivoSim Labs, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
VivoSim Labs, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 4.52 | 20.48 |
| Quick Ratio | 1.70 | 4.52 | 20.48 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.33 Million | $7.54 Million | $32.63 Million |
VivoSim Labs, Inc. - Advanced Valuation Insights
This section examines the relationship between VivoSim Labs, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.54 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | -49.6% |
| Total Assets | $7.39 Million |
| Market Capitalization | $1.92 Million USD |
Valuation Analysis
Below Book Valuation: The market values VivoSim Labs, Inc.'s assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: VivoSim Labs, Inc.'s assets decreased by 49.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for VivoSim Labs, Inc. (2011–2026)
The table below shows the annual total assets of VivoSim Labs, Inc. from 2011 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $7.39 Million | -49.58% |
| 2025-03-31 | $14.65 Million | +130.74% |
| 2024-03-31 | $6.35 Million | -68.74% |
| 2023-03-31 | $20.31 Million | -38.99% |
| 2022-03-31 | $33.30 Million | -16.59% |
| 2021-03-31 | $39.92 Million | +40.35% |
| 2020-03-31 | $28.44 Million | -29.99% |
| 2019-03-31 | $40.62 Million | -18.47% |
| 2018-03-31 | $49.83 Million | -27.97% |
| 2017-03-31 | $69.18 Million | +2.37% |
| 2016-03-31 | $67.58 Million | +26.34% |
| 2015-03-31 | $53.49 Million | +6.58% |
| 2014-03-31 | $50.19 Million | +199.64% |
| 2013-03-31 | $16.75 Million | +391689.47% |
| 2011-03-31 | $4.28K | -- |
About VivoSim Labs, Inc.
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as… Read more